Furthermore, treatment with ATRi QDx3 plus RT resulted in more CD8+ T cells in the tumor infiltrate than treatment with ATRi QDx9 plus RT, which, like in the CT26 model, nearly depleted the tumor of CD8+ T cells (Figure 7F). This evidence concerns the gene CD8A and neoplasm.